Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- Premium for Development of New Drugs Is Fiscal Neutrality System: Mr Kamoya of JPMA
November 11, 2011
- JPWA's Bessho Says Promotion of Unit-Priced Contracts by Product First and Foremost
November 11, 2011
- Trial of Premium for New Drug Development Should Continue: Dr Suzuki of JMA
November 1, 2011
- Prescription Doubts Found in 3.15% of Prescriptions, 70% of Those Were Changed: JPA Survey
October 28, 2011
- FPMAJ to Request DPJ to Make Premiums Permanent
October 27, 2011
- JPA’s Yamamoto Calls for Deliberation on TPP after Clarification
October 25, 2011
- JMA Openly Opposes TPP; JPA, JDA, JNA Express Concern
October 24, 2011
- FPMAJ Drafting GLs on Radiation Testing for Crude Drugs
October 21, 2011
- JPMA Makes Pamphlets to Promote Understanding of PC
October 20, 2011
- JPMA to Draw Up Opinion on TPP During This Month
October 20, 2011
- Toray to Join JPMA in November
October 20, 2011
- The Number of Applicants Increases 779 to 5911 for MR Exam
October 20, 2011
- Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
- JGA President Sawai Insists on Keeping 70% Rule for New Generics
October 19, 2011
- Dispensing Fees May Be Cut to Enable Hike in Medical Fees: Mr Urushibata of Chuikyo
October 18, 2011
- Vaccine Industry Must Continue to Present Proposals t oGov’t: Mr Fushimi of JAVI
October 18, 2011
- JPA Opposes TPP on Fears of Drug Safety
October 14, 2011
- Osteoporosis Foundation Survey Shows Patient Interest in Monthly BP Formulation
October 14, 2011
- CSMIC’s Kobayashi Questions Proposal to Freeze NHI Prices
October 12, 2011
- 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…